Is IDXX a Good Stock to Buy? The Bull and Bear Case (2026)

Last updated November 2026

Short answer

Both cases are real, which is why the question is contested. The bull case for IDEXX Laboratories, Inc. (IDXX) rests on The CAG Diagnostics recurring annuity: CAG Diagnostics recurring revenue was ~$975 million in Q2 2026, up ~11% as reported and ~10% organic, and it carries the bulk of company gross profit. The bear case rests on visit volume is the central risk, because if US clinic traffic keeps eroding and testing per visit stops covering the shortfall, the recurring line decelerates toward mid single digits and a ~34x forward multiple has a long way to fall. Analysts covering it publish targets from $470.00 to $810.00 against a $700.65 share price on November 16, 2026, so even the professionals disagree by 47% of their own average. We do not give a verdict. Each case is set out below at full strength, so you can decide which set of assumptions you actually believe. Walnut is not an investment adviser.

IDXX key stats

At $700.65 on November 16, 2026, IDEXX Laboratories, Inc. (IDXX) has a market cap of $55.2B and a P/E of 47.2 on trailing earnings (41.5 on forward earnings). It next reports earnings around February 1, 2027 (estimated).

Market cap
$55.2B
P/E (trailing)
47.2
P/E (forward)
41.5
EPS (trailing 12 months)
$14.84
Price to book
29.5
Beta
1.54
Next earnings
around February 1, 2027 (estimated)

Market cap, P/E and yield are measured at the $700.65 price on November 16, 2026, from Yahoo Finance figures pulled in November 2026. Earnings date from Yahoo Finance. Walnut is informational, not investment advice.

What's new with IDEXX Laboratories, Inc. (IDXX)?

The last two weeks for IDEXX Laboratories, Inc., as of November 17, 2026: the price move, the next earnings date, what the company filed with the SEC, and what analysts changed.

  • IDXX closed at $700.65 on November 16, 2026, down 0.8% over the past five trading days (from $706.65).
  • IDEXX Laboratories, Inc. next reports quarterly results around February 1, 2027 (estimated).
  • On November 3, 2026, Morgan Stanley raised its target to $810.00 from $805.00 (Overweight).
  • On November 3, 2026, UBS raised its target to $700.00 from $627.00 (Neutral).

IDEXX Laboratories, Inc. filed no current, quarterly or annual report with the SEC in the last two weeks.

Prices are daily closes from Yahoo Finance. Filings are read from SEC EDGAR every six hours. Analyst actions come from Yahoo Finance as of November 2026. Walnut is informational, not investment advice.

IDEXX Laboratories (NASDAQ: IDXX) sells diagnostics to veterinarians. Its Companion Animal Group, roughly ~92% of revenue, places in clinic analyzers (Catalyst, ProCyte, SediVue and the newer inVue Dx) into practices and then sells the consumables those instruments burn through, while a global reference laboratory network runs the panels clinics send out. Practice management software and digital imaging (ezyVet, Cornerstone, ImageVue) sit alongside the diagnostics and pull more testing through the same customers. Two smaller segments round out the business: Water, which tests drinking water for coliform bacteria, and Livestock, Poultry and Dairy. The company is headquartered in Westbrook, Maine, employs about ~11,000 people, and sells into more than 175 countries. The economics explain the multiple. CAG Diagnostics recurring revenue reached ~$975 million in the June 2026 quarter, about ~80% of total company revenue, growing ~11% as reported while capital instrument sales fell ~20%. That inversion is the model working as designed, because hardware placements are the cost of acquiring an annuity rather than the profit. What complicates the story is the denominator: US same store clinical visits fell ~1.3% in the quarter, with wellness visits down more than ~3%, so growth now comes from more testing per visit, net price and international expansion rather than more animals through the door. Investors have de rated the stock hard on that point: it closed at roughly ~$564 on October 16, 2026, down ~16% year to date and ~12% over twelve months, against a 52 week high near ~$770, even after a second quarter beat and a raised full year outlook. A bounce of about ~10% over the past month has lifted it off a 52 week low near ~$501. The newest strategic move is software. On September 30, 2026 IDEXX acquired CoVetAI, a veterinary AI platform, adding an AI tool to the practice software suite with the stated aim of pulling more diagnostic orders through the clinics that use it. Third quarter results arrive on November 2, 2026, with consensus near ~$3.70 of EPS on ~$1.19 billion of revenue.

The bull case: what would have to be true for $810.00

The most optimistic published target on IDXX is $810.00, +15.6% from the $700.65 share price on November 16, 2026. Getting there needs the following to work close to its best case, not merely to avoid going wrong.

1. The CAG Diagnostics recurring annuity

CAG Diagnostics recurring revenue was ~$975 million in Q2 2026, up ~11% as reported and ~10% organic, and it carries the bulk of company gross profit. IDEXX VetLab consumables grew ~15% and reference laboratory services ~11%, both driven by testing volume rather than price alone. The soft spot inside that line is rapid assay products, up only ~1% as the Catalyst pancreatic lipase test pulls testing onto other modalities.

2. inVue Dx and the premium installed base

The inVue Dx cellular analyzer passed ~9,000 installed instruments after more than ~1,600 placements in the June quarter, and the global premium instrument installed base grew ~11%. Each placement depresses reported capital instrument revenue in the year it lands, which is most of why that line fell ~20%, while seeding consumable demand for years. IDEXX extended the platform again in August 2026 with a dual species point of care NT proBNP cardiac test.

3. Utilization offsetting flat visit volumes

US same store clinical visits declined ~1.3% in Q2 2026, yet US CAG Diagnostics recurring revenue still grew ~9.7%. The gap is diagnostic utilization: more panels per visit, an ageing pet population that needs more screening, and net price realization. At its August 2026 investor day the company restated long term targets of more than ~10% organic revenue growth, ~50 to ~100 basis points of annual margin expansion and roughly ~15% average EPS growth, against a stated ~$45 billion global companion animal testing opportunity.

4. Margin expansion and share repurchase

Second quarter gross margin reached ~64.0% and operating margin ~35.0%, each up about ~140 basis points year over year on volume leverage and productivity work. Full year guidance now calls for an operating margin of ~32.3% to ~32.5% and EPS of ~$14.69 to ~$14.94. Average share count is being reduced ~1.5% to ~2% annually, so buybacks contribute a couple of points of the reported EPS growth on top of operations. The trailing free cash flow figure Yahoo Finance reports is ~$909M against ~$1.37B of operating cash flow, so the pace of buybacks in the second half is worth watching against the first half's ~$700M.

5. Software and AI as a testing funnel

The September 30, 2026 purchase of CoVetAI, a veterinary AI platform, extends a strategy that began with ezyVet and Cornerstone: own the software the clinic works in, and make ordering an IDEXX panel the path of least resistance. Terms were not material enough to change guidance. At a Morgan Stanley conference in September management again reaffirmed the long term growth targets and pointed to cancer testing as a next diagnostic menu expansion.

The bear case: what would have to be true for $470.00

The most pessimistic published target is $470.00, -32.9% from the current price. It is neither a floor nor a forecast; it is roughly what one analyst thinks IDEXX Laboratories, Inc. is worth if the risks below bite instead of the drivers above.

Visit volume is the central risk, because if US clinic traffic keeps eroding and testing per visit stops covering the shortfall, the recurring line decelerates toward mid single digits and a ~34x forward multiple has a long way to fall. Wellness visits, down more than ~3%, sit at the discretionary end of veterinary spending and track consumer pressure and muted puppy adoption directly. Competition is intensifying from Mars owned Antech, which absorbed Heska and can now bundle in clinic analyzers with a national laboratory network the way IDEXX does, and from Zoetis in point of care instruments. Roughly ~23% of revenue is non US, so currency both flattered first half reported growth and now costs an estimated ~$15 million against the full year outlook. Leverage is not the concern, at about ~$1.1 billion of debt against ~$197 million of cash and ~$1.6 billion of EBITDA, but the ~27% drawdown from the 52 week high is a reminder of how fast this multiple reprices when the volume narrative wobbles.

The bear case deserves the same attention as the bull case, and usually gets less. If you are holding IDXX already, these risks exist either way; what to check is whether any of them has moved from possible to actually happening in the reported numbers.

Where analysts land on IDXX

12 analysts cover IDXX, with an average target of $717.17 (+2.4% against $700.65) and a split of 9 buy, 4 hold, 1 sell. Bear in mind sell-side ratings skew positive across the whole market, so that split is not a balanced vote. The full target table, the recent rating actions by firm, and how the consensus has shifted are on the IDXX forecast and price target page.

How is IDXX valued?

Market cap, P/E and dividend yield at today's price are in the IDXX key stats above. The business figures below come from IDEXX Laboratories, Inc.'s reported results as of October 2026 and change when it next reports.

  • Revenue (TTM): ~$4.55B; Q2 2026 revenue up ~9.7% year over year
  • CAG Diagnostics recurring revenue (Q2 2026): ~$975M, up ~11%, about ~80% of total revenue
  • Margins (TTM): Gross ~62.5%, operating ~35.0%, net ~25.0%
  • Dividend: None; capital returned through buybacks
  • Next earnings: November 2, 2026; consensus EPS ~$3.70 on ~$1.19B revenue

As of October 2026: At roughly ~$564 a share and a market cap near ~$44.5B, IDEXX trades at about ~40x trailing earnings and ~34x the ~$16.73 analysts expect for 2027, and it pays no dividend. That is still a premium to the broader medical device group, though well below the multiples of 45x and above the stock carried through much of the past five years; the shares are down ~16% in 2026 and sit between a 52 week low of ~$501 and a high of ~$770. The twelve analysts Yahoo Finance tracks carry a mean target near ~$701, though JPMorgan trimmed its target to $750 from $775 on October 16.

How do you decide if IDXX is a buy?

Whether IDXX is a buy is easier to judge through four narrower questions:

  • Thesis: do you believe the bull case above, and is it still true today?
  • Time horizon: a single stock can be volatile, so a longer horizon absorbs more of the swings.
  • Position sizing: a thesis can be right and the sizing still wrong; decide how much of your portfolio one name should be.
  • Overlap: check whether you already hold IDXX indirectly through an index or sector ETF before adding more.

What would change your mind on IDXX

Write the tripwires down before you need them. Deciding what would falsify your view is far harder once a position is moving against you.

  • Bull case breaks if: The CAG Diagnostics recurring annuity stalls in the reported numbers. A shift in the narrative around them is not enough on its own.
  • Bear case breaks if: visit volume is the central risk, because if US clinic traffic keeps eroding and testing per visit stops covering the shortfall, the recurring line decelerates toward mid single digits and a ~34x forward multiple has a long way to fall fails to materialise over several reporting periods while the drivers keep compounding.
  • Neither matters if: the position has grown large enough that being wrong would damage the whole portfolio. Sizing overrides the argument.

For the full picture, see the IDXX stock guide (what the company does, the ETFs that hold it, similar stocks, and the themes it fits). In Walnut you can ask its AI about IDXX against your real portfolio and see your actual exposure before deciding.

Your questions about IDEXX Laboratories, Inc.

Ask Walnut's AI anything about IDXX and see how it fits what you own.

FAQ

Is IDXX a good stock to buy right now?

+

That depends on which case you find more convincing, and both are on this page. The bull case rests on The CAG Diagnostics recurring annuity, with revenue (ttm) at ~$4.55B; Q2 2026 revenue up ~9.7% year over year. The bear case rests on visit volume is the central risk, because if US clinic traffic keeps eroding and testing per visit stops covering the shortfall, the recurring line decelerates toward mid single digits and a ~34x forward multiple has a long way to fall. Analysts covering it are spread from $470.00 to $810.00, a spread wide enough to show the question is contested. If you believe the thesis, the questions that matter next are sizing and overlap; timing comes after. Walnut is not an investment adviser and this is not a recommendation.

Should I sell IDXX?

+

Nobody can answer that for you, and a more useful version of the question is narrower: has anything changed in the reason you bought it? The bear case on this page is the place to check. Visit volume is the central risk, because if US clinic traffic keeps eroding and testing per visit stops covering the shortfall, the recurring line decelerates toward mid single digits and a ~34x forward multiple has a long way to fall. If that risk is what you were worried about and it is now playing out, take it seriously. If the price simply fell while the thesis held, the situation is different. The most pessimistic published target is $470.00, -32.9% from the $700.65 price, which is one analyst's downside case. It is not a floor. Walnut is not an investment adviser.

What is the bull case for IDXX?

+

The CAG Diagnostics recurring annuity. CAG Diagnostics recurring revenue was ~$975 million in Q2 2026, up ~11% as reported and ~10% organic, and it carries the bulk of company gross profit. The most optimistic analyst target on IDXX is $810.00, +15.6% from the $700.65 price. That figure is only reachable if this thesis works close to its best case.

What is the bear case for IDXX?

+

Visit volume is the central risk, because if US clinic traffic keeps eroding and testing per visit stops covering the shortfall, the recurring line decelerates toward mid single digits and a ~34x forward multiple has a long way to fall. Wellness visits, down more than ~3%, sit at the discretionary end of veterinary spending and track consumer pressure and muted puppy adoption directly. Competition is intensifying from Mars owned Antech, which absorbed Heska and can now bundle in clinic analyzers with a national laboratory network the way IDEXX does, and from Zoetis in point of care instruments. Roughly ~23% of revenue is non US, so currency both flattered first half reported growth and now costs an estimated ~$15 million against the full year outlook. Leverage is not the concern, at about ~$1.1 billion of debt against ~$197 million of cash and ~$1.6 billion of EBITDA, but the ~27% drawdown from the 52 week high is a reminder of how fast this multiple reprices when the volume narrative wobbles. The most pessimistic published target is $470.00, -32.9% from the current price, which is roughly what one analyst thinks the stock is worth if these risks bite and the drivers do not.

What does IDEXX Laboratories, Inc. do?

+

Veterinary diagnostics leader that places analyzers in vet clinics and earns recurring revenue from test consumables and its global reference laboratory network.

What would have to change for IDXX to stop being worth holding?

+

Decide that in advance, because it is far harder to think clearly once a position is moving against you. The concrete tripwires here: the driver behind the bull case (The CAG Diagnostics recurring annuity) stalling in the reported numbers (a change in the narrative alone does not count), the risk above (visit volume is the central risk, because if US clinic traffic keeps eroding and testing per visit stops covering the shortfall, the recurring line decelerates toward mid single digits and a ~34x forward multiple has a long way to fall) turning from a possibility into a reported fact, or the position growing large enough that a bad outcome would matter to your whole portfolio regardless of who is right.

What does IDEXX Laboratories do?

+

IDEXX sells diagnostics to veterinary practices. It places blood chemistry, hematology and urinalysis analyzers inside clinics, sells the consumables those instruments use, and runs a global reference laboratory network for tests clinics send out. Smaller Water and Livestock, Poultry and Dairy segments test drinking water and farm animals. Companion animal work is roughly ~92% of revenue.

What is IDEXX's razor and blade model?

+

The analyzer is the razor and the test consumable is the blade. IDEXX places Catalyst, ProCyte, SediVue and inVue Dx instruments into practices at modest instrument revenue, then earns for years on slides, cartridges and reagents. Capital instrument sales fell ~20% in Q2 2026 while the recurring consumable and laboratory revenue they generate grew ~11%, which is the intended shape.

How much of IDEXX's revenue is recurring?

+

CAG Diagnostics recurring revenue was ~$975 million of ~$1.22 billion in total Q2 2026 revenue, about ~80%. Add recurring veterinary software revenue of ~$76 million and the share of the quarter that repeats rises to roughly ~86%. Capital instrument sales were only ~$47 million, or about ~4% of the quarter.

Walnut is informational, not investment advice, and gives no verdict on IDXX. Analyst targets referenced here come from a November 2026 pull of published third-party research and change constantly. The share price is the last one Yahoo Finance reported on November 16, 2026. Verify current figures with your broker before acting on them.

The case for and against similar stocks